➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Colorcon
Medtronic
McKesson
Boehringer Ingelheim

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MANNITOL

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Mannitol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003062 ↗ Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 2 1997-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effect of temozolomide in patients with progressive or recurrent stage IV non-small cell lung cancer, with or without brain metastases, who have not been treated for metastatic disease with chemotherapy.
NCT00004767 ↗ Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders Completed Johns Hopkins University Phase 2 1985-01-01 OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00004767 ↗ Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders Completed National Center for Research Resources (NCRR) Phase 2 1985-01-01 OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00111956 ↗ Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) N/A 2004-04-01 Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.
NCT00113854 ↗ Mannitol as Adjunct Therapy for Childhood Cerebral Malaria Unknown status Makerere University Phase 3 2004-10-01 Cerebral malaria is a life-threatening complication of Plasmodium falciparum infection in African children and nonimmune travellers despite availability of quinine, the current drug of choice. Several reports have suggested that raised intracranial pressure (ICP) is a major cause of death among children with cerebral malaria. Mannitol, an osmotic diuretic, effectively lowers ICP and is used to treat post traumatic raised ICP. There have been some case reports of reduction in mortality and morbidity in African children with cerebral malaria following administration of mannitol, but as these were not randomized controlled trials it is difficult to evaluate their significance. This study seeks to establish whether a single dose of intravenous mannitol given to children with cerebral malaria will significantly reduce the coma recovery time.
NCT00117182 ↗ Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD Completed Pharmaxis Phase 2 2005-07-01 The purpose of this study is to determine whether the Aridol (mannitol) challenge test can predict response to treatment with inhaled corticosteroids in COPD subjects. Subjects will undergo an Aridol test and then 3 months of treatment with inhaled corticosteroids. The effect on lung function and quality of life will then be measured and correlated with the Aridol test result.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mannitol

Condition Name

Condition Name for Mannitol
Intervention Trials
Asthma 20
Cystic Fibrosis 9
Healthy 7
Traumatic Brain Injury 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mannitol
Intervention Trials
Asthma 18
Intracranial Hypertension 12
Fibrosis 9
Cystic Fibrosis 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mannitol

Trials by Country

Trials by Country for Mannitol
Location Trials
United States 141
United Kingdom 39
Canada 33
Australia 30
Italy 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mannitol
Location Trials
New York 18
Massachusetts 10
Ohio 8
Minnesota 8
Oregon 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mannitol

Clinical Trial Phase

Clinical Trial Phase for Mannitol
Clinical Trial Phase Trials
Phase 4 37
Phase 3 31
Phase 2/Phase 3 9
[disabled in preview] 73
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mannitol
Clinical Trial Phase Trials
Completed 84
Recruiting 39
Not yet recruiting 27
[disabled in preview] 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mannitol

Sponsor Name

Sponsor Name for Mannitol
Sponsor Trials
Pharmaxis 19
OHSU Knight Cancer Institute 6
National Cancer Institute (NCI) 6
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mannitol
Sponsor Trials
Other 256
Industry 53
NIH 16
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
McKesson
Harvard Business School
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.